Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.17.20 extracted from

  • Muto, Y.; Suzuki, K.; Iida, H.; Sakakibara, S.; Kato, E.; Itoh, F.; Kakui, N.; Ishii, H.
    EF6265, a novel thrombin-activatable fibrinolysis inhibitor-a inhibitor, protects against sepsis-induced organ dysfunction in rats (2009), Crit. Care Med., 37, 1744-1749.
    View publication on PubMed
Search for more literature for 3.4.17.20

Application

Application Comment Organism
medicine TAFI plays an important role in the deterioration of organ dysfunction in sepsis and the inhibitor of TAFIa protects against sepsis-induced tissue damage through regulation of fibrinolysis and inflammation Rattus norvegicus

Inhibitors

Inhibitors Comment Organism Structure
EF6265 specific inhibitor of activated form of TAFIa. A pharmacologic study to assess the effect of EF6265 on rat sepsis-induced organ dysfunction models is performed. In the endotoxemia model, posttreatment with EF6265 reduces fibrin deposits in the kidney and liver accompanied by no significant changes in platelet count and fibrinogen concentration in plasma. EF6265 also significantly decreases levels of plasma lactate dehydrogenase and aspartate aminotransferase, markers of organ dysfunction. In the sepsis model, EF6265, simultaneously administered with ceftazidime (CAZ) 2 h after Pseudomonas aeruginosa injection dramatically potentiates the interleukin-6-reducing effect of CAZ in plasma. This combined treatment also lowers plasma lactate dehydrogenase and blood urea nitrogen more potently than single treatment with CAZ Rattus norvegicus

Organism

Organism UniProt Comment Textmining
Rattus norvegicus
-
-
-

Synonyms

Synonyms Comment Organism
TAFI
-
 Rattus norvegicus
thrombin-activatable fibrinolysis inhibitor
-
 Rattus norvegicus